# A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

> **NCT01536743** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Ovarian Epithelial Carcinoma

## Interventions

- **DRUG:** PD0332991

## Key facts

- **NCT ID:** NCT01536743
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-15
- **Primary completion:** 2020-02-24
- **Final completion:** 2020-02-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536743, "A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01536743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*